{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:40:56Z","timestamp":1794487256987,"version":"4.9.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018688","name":"Korea Disease Control and Prevention Agency","doi-asserted-by":"publisher","award":["6236-302-210-13"],"award-info":[{"award-number":["6236-302-210-13"]}],"id":[{"id":"10.13039\/100018688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.04.002","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T15:22:29Z","timestamp":1681226549000},"page":"3106-3110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity and Protective Efficacy of Recombinant Protective Antigen Anthrax Vaccine (GC1109) in A\/J Mice Model"],"prefix":"10.1016","volume":"41","author":[{"given":"Gyu-Lee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Wook","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwajung","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-5907","authenticated-orcid":false,"given":"So-Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwachul","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ah","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Rang","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ho","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Kyoung","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-eun","family":"Rhie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.04.002_b0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.12998\/wjcc.v3.i1.20","article-title":"Anthrax: A disease of biowarfare and public health importance","volume":"3","author":"Goel","year":"2015","journal-title":"World J Clin Cases"},{"issue":"11","key":"10.1016\/j.vaccine.2023.04.002_b0010","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/CVI.00324-12","article-title":"A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques","volume":"19","author":"Quinn","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.002_b0015","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/21645515.2020.1799668","article-title":"Characterization of the UK anthrax vaccine and human immunogenicity","volume":"17","author":"Modi","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.04.002_b0020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.mam.2009.08.006","article-title":"Anthrax vaccination strategies.","volume":"30","author":"Cybulski","year":"2009","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.vaccine.2023.04.002_b0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/17460913.4.1.35","article-title":"Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax","volume":"4","author":"Schneemann","year":"2009","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2023.04.002_b0030","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2105\/AJPH.52.4.632","article-title":"Field Evaluation of a Human Anthrax Vaccine","volume":"52","author":"Brachman","year":"1962","journal-title":"Am J Public Health Nations Health"},{"issue":"23-24","key":"10.1016\/j.vaccine.2023.04.002_b0035","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1016\/S0264-410X(01)00021-4","article-title":"Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin","volume":"19","author":"Fellows","year":"2001","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2023.04.002_b0040","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.7205\/MILMED-D-15-00485","article-title":"Anthrax Vaccine and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus in the U.S. Military: A Case-Control Study","volume":"181","author":"Bardenheier","year":"2016","journal-title":"Mil Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.002_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-019-0102-z","article-title":"Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge","volume":"4","author":"Weir","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"29","key":"10.1016\/j.vaccine.2023.04.002_b0050","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1016\/j.vaccine.2019.05.057","article-title":"Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study","volume":"37","author":"Kang","year":"2019","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2023.04.002_b0055","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2019.12.048","article-title":"Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model","volume":"38","author":"Jo","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.002_b0060","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.femsim.2005.05.008","article-title":"Expression and secretion of the protective antigen of Bacillus anthracis in Bacillus brevis","volume":"45","author":"Rhie","year":"2005","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2023.04.002_b0065","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0264-410X(95)00139-R","article-title":"Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs","volume":"13","author":"Ivins","year":"1995","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2023.04.002_b0070","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1016\/j.vaccine.2017.07.076","article-title":"Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate","volume":"35","author":"Savransky","year":"2017","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2023.04.002_b0075","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"151","key":"10.1016\/j.vaccine.2023.04.002_b0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004073","article-title":"Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge","volume":"4","author":"Fay","year":"2012","journal-title":"Sci Transl Med"},{"issue":"51","key":"10.1016\/j.vaccine.2023.04.002_b0085","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1016\/j.vaccine.2016.04.048","article-title":"Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge","volume":"34","author":"Sivko","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:31Z","timestamp":1759404331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23003869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":17,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X23003869"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.002","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and Protective Efficacy of Recombinant Protective Antigen Anthrax Vaccine (GC1109) in A\/J Mice Model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}